Publications by authors named "Tomoka Yoda"
Aim: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear.
View Article and Find Full Text PDFBackground And Aims: The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these patients remain unclear. We aimed to close these gaps.
Methods: We retrospectively screened patients with newly diagnosed non-HBV-related-HCC (standard HBsAg-test negative) at Hokkaido University.
Article Synopsis
- - The study focused on the impact of muscle atrophy and high subcutaneous adipose tissue (SAT) radiodensity on prognosis in patients with hepatocellular carcinoma (HCC).
- - In a retrospective analysis of 201 patients, it was found that those with muscle atrophy (33.3%) and high SAT radiodensity (12.9%) had significantly worse survival outcomes compared to those without these conditions.
- - The findings suggest that recognizing patients with both muscle atrophy and high SAT radiodensity is crucial for developing targeted interventions, like nutritional therapy and exercise, to improve their health outcomes.
Article Synopsis
- Lenvatinib, a treatment for unresectable hepatocellular carcinoma (HCC), can lead to appetite loss, but the reasons and effects were previously unclear.
- The study examined how changes in the hormone FGF21 during treatment relate to appetite changes in 63 HCC patients, measuring FGF21 levels at different times after starting lenvatinib.
- Findings revealed that patients who experienced significant appetite loss had a notable increase in FGF21 levels after 4 weeks of treatment, suggesting that monitoring FGF21 could help predict which patients are at higher risk for appetite loss and better understand the treatment’s side effects.
Article Synopsis
- The study investigates the recent prevalence of hepatitis delta virus (HDV) infections among patients with hepatitis B virus (HBV) in Japan, as it has not been updated for over two decades.
- Researchers screened 1,264 HBV patients at Hokkaido University Hospital, concluding that 1.7% had detectable anti-HDV antibodies.
- The findings indicate that those with anti-HDV antibodies had a higher prevalence of liver cirrhosis and experienced faster progression of liver fibrosis, emphasizing the need for routine HDV testing in similar patients.
Aim: Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct-acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify long-term changes in the prevalence of fatty liver and hyper-low-density lipoprotein (LDL) cholesterolemia and their associations in patients who achieve successful HCV eradication using DAAs.
View Article and Find Full Text PDFThe possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated.
View Article and Find Full Text PDFEpo-C12 is a synthetic derivative of epolactaene, isolated from Penicillium sp. BM 1689-P. Epo-C12 induces apoptosis in human acute lymphoblastoid leukemia BALL-1 cells.
View Article and Find Full Text PDF